**Robert P. Giugliano, MD, FACC**
**Prof Medicine**
TIMI Study Group at BWH

**Printed as of 11/15/2026**

# Disclosures

## Personal Commercial (38)

| Company Name | Relationship Category | Compensation Level | *Topic Area(s)* |
|---|---|---|---|
| ***Self*** | | | |
| Academy Continued Healthcare Learning | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Amgen | Research/Research Grants<br>‡ *VESALIUS-CV* | Significant (>= $5,000) | *Prevention* |
| Amgen | Research/Research Grants<br>‡ *FOURIER-OLE* | Significant (>= $5,000) | *Prevention* |
| Amgen Inc. | Consultant Fees/Honoraria | Significant (>= $5,000) | |
| Anthos Therapeutics | Research/Research Grants<br>‡ *AZALEA-TIMI 71 OLE* | Significant (>= $5,000) | *Arrhythmias and Clinical EP* |
| Anthos Therapeutics | Research/Research Grants<br>‡ *LILAC-TIMI 76* | Significant (>= $5,000) | *Arrhythmias and Clinical EP* |
| Artivion | Data Safety Monitoring Board | Significant (>= $5,000) | *Valvular Heart Disease* |
| Beckman Coulter | Other - *Clinical Endpoint Committee* | Modest (< $5,000) | *Acute Coronary Syndromes* |
| Big Sky Cardiology | Consultant Fees/Honoraria | Modest (< $5,000) | |
| CADECI | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Celecor | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Centrix | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Daiichi Sankyo | Other - *Lecturer and Consultant* | Significant (>= $5,000) | *Arrhythmias and Clinical EP* |
| Daiichi Sankyo | Research/Research Grants | Significant (>= $5,000) | *Arrhythmias and Clinical EP* |
| Dr. Reddy's Laboratories Inc. | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Gilead Sciences, Inc. | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Inari | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Inventiva | Consultant Fees/Honoraria | Modest (< $5,000) | |
| IONIS | Research/Research Grants | Significant (>= $5,000) | |
| Korean Heart Rhythm Society | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Medcon | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Medical Education Resources | Other - *CME Lectures* | Significant (>= $5,000) | *General Cardiology* |
| Medpace, Inc | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Menarini | Other - *Lecturer* | Significant (>= $5,000) | *Arrhythmias and Clinical EP* |
| Novartis Corporation | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Novartis Corporation | Research/Research Grants | Significant (>= $5,000) | |
| Parexel | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Perosphere | Consultant Fees/Honoraria | Modest (< $5,000) | |
| PhaseBio | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Radcliffe Med Ed | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Samsung | Consultant Fees/Honoraria | Significant (>= $5,000) | *Arrhythmias and Clinical EP* |
| Samsung | Other - *Adjudicator* | Significant (>= $5,000) | *Arrhythmias and Clinical EP* |
| Sanofi-Aventis | Consultant Fees/Honoraria | Modest (< $5,000) | *General Cardiology* |

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|---|---|
| Scleroderma Research Foundation, Inc | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Servier | Other - *CME Lecture* | Modest (< $5,000) | *Arrhythmias and Clinical EP* |
| SHAKEHEART | Consultant Fees/Honoraria | Modest (< $5,000) | |
| Shanghai Medical Technology | Other - *Lecture, interview* | Modest (< $5,000) | *Arrhythmias and Clinical EP Prevention* |
| SUMMEET | Consultant Fees/Honoraria | Modest (< $5,000) | |

## Additional Personal Commercial Disclosures for Education Activities (1)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|---|---|
| *Self* | | | |
| Thrombosis Research Institute | Consultant Fees/Honoraria | Modest (< $5,000) | *Arrhythmias and Clinical EP* |

## Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|---|---|
| *Self* | | | |
| Syneos | Other - *Clinical Endpoint Committee* | Modest (< $5,000) | *Other* |

## Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (1)

| Year | Case Title | Represented | Description | Compensation |
|---|---|---|---|---|
| *Self* | | | | |
| 2023 | Acute Coronary Syndrome | Plaintiff | Elderly woman with type 2 NSTEMI complicating an acute abdomen | Modest (< $5,000) |

*† Commercial Funding Source | ‡ Trial Name*

# Agreement

## Certified Education Attestation | Signed on 7/21/2025

*URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement*

## Confidentiality, Disclosure and Assignment Agreement | Signed on 7/21/2025

*URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement*

## Embargo | Signed on 7/21/2025

*URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement*

## On-Going Obligation Agreement | Signed on 7/21/2025

### ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.